FAZIO, CAROLINA
 Distribuzione geografica
Continente #
NA - Nord America 822
EU - Europa 615
AS - Asia 87
AF - Africa 2
SA - Sud America 1
Totale 1.527
Nazione #
US - Stati Uniti d'America 821
IE - Irlanda 167
IT - Italia 127
GB - Regno Unito 123
CN - Cina 52
SE - Svezia 50
UA - Ucraina 32
FR - Francia 26
DE - Germania 25
RU - Federazione Russa 24
SG - Singapore 18
ES - Italia 15
FI - Finlandia 13
VN - Vietnam 12
BE - Belgio 3
CH - Svizzera 2
HR - Croazia 2
PL - Polonia 2
BO - Bolivia 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KG - Kirghizistan 1
MA - Marocco 1
MY - Malesia 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 1.527
Città #
Dublin 167
Fairfield 156
Southend 112
Woodbridge 83
Ashburn 68
Cambridge 63
Seattle 57
Wilmington 57
Houston 56
New York 40
Chandler 30
Jacksonville 30
Siena 27
Ann Arbor 25
Princeton 23
Beijing 18
Shanghai 15
Málaga 14
Dong Ket 11
Helsinki 11
San Diego 11
San Mateo 11
Singapore 10
Fremont 7
Dearborn 6
Nanjing 5
San Giovanni Valdarno 5
Labico 4
Milan 4
Montevarchi 4
Palermo 4
Redwood City 4
Venezia 4
Asciano 3
Boardman 3
Brussels 3
Empoli 3
Hounslow 3
Lavis 3
Moscow 3
Rome 3
Santa Clara 3
Altamura 2
Chiswick 2
Chiusdino 2
Düsseldorf 2
Florence 2
Novara 2
Pistoia 2
Salerno 2
Sesto Fiorentino 2
Zagreb 2
Zurich 2
Arezzo 1
Ascoli Piceno 1
Athens 1
Bishkek 1
Bratislava 1
Brno 1
Centurion 1
Changsha 1
Chicago 1
Ferentino 1
Figline Valdarno 1
Guangzhou 1
Guiyang 1
Haikou 1
Hefei 1
Hong Kong 1
Jiaxing 1
Jinan 1
Kilburn 1
La Paz 1
Lanzhou 1
London 1
Los Angeles 1
Madrid 1
Naples 1
Ningbo 1
Norwalk 1
Phoenix 1
Reggio Calabria 1
Roseto Degli Abruzzi 1
San Francisco 1
Scarperia 1
Sollentuna 1
Stagno 1
Stockholm 1
Tallinn 1
Tel Aviv 1
Torino 1
Trieste 1
Wandsworth 1
Warsaw 1
Zhengzhou 1
Totale 1.233
Nome #
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 211
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 177
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 152
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 140
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 129
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 124
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 115
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 108
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 98
ICOS expression as immunologic marker in immune activating monoclonal antibodies 73
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 62
null 58
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 57
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 39
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 34
Totale 1.577
Categoria #
all - tutte 5.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.786


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020396 0 0 6 39 59 38 52 66 57 39 17 23
2020/2021363 15 36 26 40 51 31 15 45 14 42 13 35
2021/2022183 8 34 17 6 8 10 10 6 3 19 31 31
2022/2023213 15 13 36 17 12 38 9 16 24 16 10 7
2023/2024277 9 4 30 9 9 95 94 5 5 0 12 5
2024/202553 17 14 22 0 0 0 0 0 0 0 0 0
Totale 1.577